Authors: Roisin Conneely, Future Science Group
Findings from an ongoing Phase III study investigating first-line non-small cell lung cancer (NSCLC) patients who have a high tumor mutation burden (TMB) have been announced by Bristol-Myers Squibb (NY, USA), demonstrating promising progression-free survival rates.
The CheckMate-227 study enrolled over 2500 non-small cell lung cancer (NSCLC) patients, randomized across squamous and non-squamous histologies, treated with a combination of Opdivo® (nivolumab) and Yervoy® (ipilimumab) versus standard chemotherapy.
The patients also expressed high TMB, regardless of PD-L1 expression. TMB is classified as ten or more mutations per megabase, a measure which is emerging as a useful oncologic biomarker.
- NEWS: Nivolumab given the green light by NICE for non-small cell lung cancers
- Review– Immunotherapy for non-small-cell lung cancer: the past 10 years
- OCTalks: Could nivolumab past 1 year improve progression free survival in pretreated NSCLC?
Bristol-Myers Squibb stated that the current findings are based on Part 1 of the trial’s investigation, comprising Part 1a, examining Opdivo and Yervoy and monotherapy versus chemotherapy in patients whose tumors express PD-L1, and